Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.55 |
| ▸ | FNTA | P49354 | 9/20 | 0.49 |
| ▸ | FNTB | P49356 | 9/20 | 0.49 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11141977 | 1.00 | FOLH1 (0.55) | FOLH1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL9561661 | 1.00 | FOLH1 (0.55) | FOLH1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL31372921 | 1.00 | FOLH1 (0.55) | FOLH1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL30051570 | 0.97 | FOLH1 (0.52) | FOLH1FNTAFNTBPGGT1BLMNA | |
| Acetic Acid SCHEMBL11146195 | 0.97 | FOLH1 (0.52) | FOLH1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL10584525 | 0.96 | FOLH1 (0.55) | FOLH1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL30052879 | 0.96 | FOLH1 (0.55) | FOLH1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL10584515 | 0.96 | FOLH1 (0.55) | FOLH1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL29714933 | 0.96 | FOLH1 (0.55) | FOLH1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL30052798 | 0.94 | FOLH1 (0.50) | FOLH1FNTAFNTBPGGT1BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | claimed |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | PHEON THERAPEUTICS LTD (GB) | 2026-01-29 | — | — | US | claimed |
| EP-4659591-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | House Foods Group Inc. (JP) | 2025-12-10 | — | — | EP | claimed |
| EP-4594520-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2025-08-06 | — | — | EP | claimed |
| WO-2025149667-A1 | ANTIBODY DRUG CONJUGATES AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2025-07-17 | — | — | WO | claimed |
| EP-4554623-A1 | ANTIBODY DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | Pheon Therapeutics Ltd (GB) | 2025-05-21 | — | — | EP | claimed |
| EP-4554624-A1 | ANTIBODY-DRUG CONJUGATES | Pheon Therapeutics Ltd (GB) | 2025-05-21 | — | — | EP | claimed |
| CN-119836306-A | Antibody drug conjugates that bind CDCP1 and uses thereof | 费恩治疗有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-119836305-A | Antibody-drug conjugates | 费恩治疗有限公司 | 2025-04-15 | — | — | CN | claimed |
| US-20250092407-A1 | METHOD FOR SYNTHESIS, ASSEMBLY AND FUNCTION TEST OF ARTIFICIAL CHLOROPLAST GENOME OF CHLAMYDOMONAS REINHARDTII | SHENZHEN UNIVERSITY (CN) | 2025-03-20 | — | — | US | claimed |
| WO-2024069235-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2024-04-04 | — | — | WO | claimed |
| WO-2024026923-A1 | METHOD FOR SYNTHESIS AND ASSEMBLY AND FUNCTIONAL TEST OF ARTIFICIAL CHLAMYDOMONAS REINHARDTII CHLOROPLAST GENOME | 深圳大学 | 2024-02-08 | — | — | WO | claimed |
| WO-2024013724-A1 | ANTIBODY-DRUG CONJUGATES | PHEON THERAPEUTICS LTD (GB) | 2024-01-18 | — | — | WO | claimed |
| WO-2024013723-A1 | ANTIBODY DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2024-01-18 | — | — | WO | claimed |
| EP-3954697-B1 | FLUORESCENT PROBE FOR DETECTING CALPAIN ACTIVITY | UNIV TOKYO (JP) | 2024-01-03 | — | — | EP | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-RE49518-E1 | Fluorescent probe for detecting calpain activity | THE UNIVERSITY OF TOKYO (JP) | 2023-05-02 | — | — | US | claimed |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | IMMUNOGEN, INC. (US) | 2023-03-30 | — | — | US | claimed |
| CN-115807021-A | Method for synthesizing, assembling and testing functions of artificial chloroplast genome of chlamydomonas reinhardtii | 深圳大学 | 2023-03-17 | — | — | CN | claimed |
| WO-2022148418-A1 | PHARMACEUTICAL COMPOSITION CAPABLE OF BEING DELIVERED BY METERED DOSE INHALER | 江苏恒瑞医药股份有限公司 | 2022-07-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | GABBR2, GABRB1, GABRB2 | FOLH1 3658/4885FNTA 3505/4885FNTB 3093/4885 |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | SLC3A2, MTCL3, SLC13A2 | FOLH1 462/4885FNTA 3528/4885FNTB 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.